AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04098159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: duplex ultrasound
Description: regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion
Study NCT00710060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Popular Opinion Leader (C-POL)
Description: The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
Study NCT00710060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/STD educational materials
Description: Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
Study NCT00710060 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV/STD educational materials
Description: Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
Study NCT00203931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Study NCT00203931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT00203931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT02255734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Study NCT02255734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Study NCT00500695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing
Study NCT04069273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Monotherapy
Description: Pembrolizumab 200 mg IV
Study NCT04069273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 10 mg/kg IV
Study NCT04069273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m2 IV
Study NCT00500695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation
Study NCT01194115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cephalexin & metronidazole
Description: cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
Study NCT01194115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo representing standard of care
Study NCT03197493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa 25-100 mg
Description: High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
Study NCT03931577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C-reactive protein rapid testing
Description: Continuous (workshop and monthly web-based training) disease-focused intervention with the provision of CRP rapid testing in the primary care practices.
Study NCT03931577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Communication skill enhancement
Description: Continuous (on-site and monthly online training) illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) in the primary care practices.
Study NCT02505932 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopic Latarjet procedure
Description: arthroscopic approach (set Depuy-Mitek, Raynham, MA)
Study NCT02505932 — intervention group
Intervention type: PROCEDURE
Intervention: Mini-open Latarjet procedure
Description: mini-open approach (set Arthrex, Naples, FL)
Study NCT00788840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulatard
Description: Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
Study NCT00788840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Detemir insulin used as long-acting insulin in treatment phase of study.
Study NCT02672904 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser
Description: surgical removal of carcinoma from the vocal cords with CO2 laser
Study NCT01053078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days
Study NCT02672904 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KTP laser
Description: surgical removal of carcinoma from the vocal cords with KTP laser
Study NCT01801059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive patient activation intervention by educational video and brochure
Study NCT01801059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive patient activation intervention by educational video and brochure
Study NCT01801059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive patient activation intervention by educational video
Study NCT01801059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive patient activation intervention by educational video
Study NCT01801059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01801059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00533390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: 600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
Study NCT00533390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: 600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
Study NCT01053078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 month treatment; placebo tablet once daily for 28 days
Study NCT01866995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raylis
Description: Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)
Study NCT01866995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard prostatostasis therapy
Study NCT01866995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard prostatostasis therapy
Study NCT03927742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape + app without messaging
Description: Shade wearable device and application without UV messaging activated
Study NCT04949984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: BLT consisted of 30-minute morning sessions with an intensity of 10,000 lux, five days a week (Monday to Friday), for 4 weeks.
Study NCT02306434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy by iCBT
Description: Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
Study NCT02306434 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care-counselling
Description: Standard care (Counselling by midwives)
Study NCT02046499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin will be administered intravenously as per standard protocol
Study NCT02046499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin ergometrine
Description: Oxytocin ergometrine will be administered intra-musculalry
Study NCT02757261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Low-level laser therapy administrated to acupoints
Study NCT02757261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Description: Occlusal splint with expander
Study NCT02067247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeamMed Speed-of-Sound bone strength test at forearm
Description: BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test
Study NCT04344067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Far Infrared Therapy
Description: The WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used to conduct FIR therapy in this study. The electrified ceramic plates of the emitter generated electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 milliwatt (mw) /cm2 when the top radiator was set at a distance of 30 and 20 cm above the skin surface respectively.
Study NCT00693992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00693992 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00693992 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT00693992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00693992 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00693992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT02614976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Padding
Description: Padding webrill (Covidian) TM 6
Study NCT03697291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS wire
Description: The wiring connection used to convey ECG signal from inside the body
Study NCT03697291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS wire
Description: The wiring connection used to convey ECG signal from inside the body
Study NCT03155750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zero Time Exercise
Description: Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
Study NCT03155750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: We offer a 2-session education course to teach the subjects about sleep hygiene practice.
Study NCT02473614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music Glove
Description: Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimum of 3 hours per week.
Study NCT02473614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hand Exercise Program
Description: Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimum of 3 hours per week.
Study NCT01600300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tesmac
Description: Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
Study NCT02729259 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Reality Snowworld
Description: The subjects will receive Virtual Reality Snowworld during their wound care procedure. The nurse will be doing their wound care.
Study NCT02729259 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Reality slides of nature
Description: The subjects will receive Virtual Reality Slides of Nature during their wound care procedure. The nurse will be doing their wound care.
Study NCT02729259 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control standard nurse wound care
Description: The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
Study NCT00884117 — intervention group
Intervention type: DRUG
Intervention: Oseltamivir
Description: Participants may receive treatment at the discretion of the investigator according to local practice standards, and there is no protocol-specified intervention. However, analyses will be presented separately for participants treated with oseltamivir during the course of the study.
Study NCT01861743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Analgesia
Description: Subjects are given medications preop, intraop and postop that implement a multi-modal approach to managing pain.
Study NCT01861743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: Subjects will be treated with patient controlled narcotic analgesia for pain management.
Study NCT01626482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: The taping consisted of two strips of material in the form of I on both sides of the lumbar spine, from the sacroiliac joint to the ipsilateral transverse process of D12.
Study NCT01626482 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo taping consisted of two 10 cm length strips of the same material, adhered transversely to the skin of the paravertebral muscles fibers
Study NCT01969773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
Study NCT01969773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline instillation
Description: Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
Study NCT03303313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Subcutaneous (sc) injection of Cemdisiran
Study NCT02140151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5mg
Study NCT02926443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Extremity Neuromuscular Training Program
Description: Neuromuscular and strengthening shoulder exercises in a group setting.
Study NCT02926443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physiotherapy Care
Description: One-on-one physiotherapy care in a clinical setting.
Study NCT03838536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Egg Powder
Description: Breastfeeding mothers will consume the equivalent of 5 whole eggs per week for 3 months.
Study NCT03838536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Egg White Powder
Description: Breastfeeding mothers will consume the equivalent of 5 egg whites per week for 3 months.
Study NCT02240212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.
Study NCT02240212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel sourced locally will be administered IV
Study NCT00722969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib + erlotinib
Description: sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral
Study NCT00677664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer acetate (Copaxone)
Description: Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
Study NCT00677664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
Study NCT02021929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib is a kinase inhibitor indicated for the treatment of:~* Unresectable hepatocellular carcinoma~* Advanced renal cell carcinoma~* Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment
Study NCT02021929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01967862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo CT
Study NCT01967862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone scan
Description: Undergo bone scan
Study NCT01967862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-Tesla magnetic resonance imaging
Description: Undergo axial MRI
Study NCT01967862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo WB MRI
Study NCT01967862 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 sodium fluoride
Description: Undergo fluorine F 18 sodium fluoride PET/CT
Study NCT01967862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo fluorine F 18 sodium fluoride PET/CT
Study NCT01967862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo fluorine F 18 sodium fluoride PET/CT
Study NCT01967862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04756882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500 UNT
Description: Anaerobic fermentation of the bacterium Clostridium botulinum produces botulinum toxin. A range of different C. Botulinum strains have been recognized; eight immunologically different serotypes (type A-H) are created and consist of botulinum neurotoxin complexed with a number of related proteins.~Neurotoxin type A preparations are the most widely used for therapeutic application. There are currently three leading botulinum neurotoxin type A (BoNT/A) products on the market in the Western Hemisphere: onabotulinumtoxinA (ONA; Botox/Vistabel, Allergan Inc., Irvine, CA, USA), abobotulinum toxin A (ABO; Dysport/Ipsen Limited, Slough Berkshire, UK), and incobotulinum toxin A (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany). In nature, BoNT-A is synthesized as macromolecular protein complexes
Study NCT02757261 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo laser
Description: Placebo laser (Low-level laser therapy administrated to acupoints)
Study NCT01650480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HELP-COPD action plan
Description: The trial specialist nurse trained in palliative aspects of respiratory care will arrange a meeting to suit the patients' clinical condition and convenience. During the meeting the HELP-COPD action plan will be worked through by the patient and study nurse, and any areas of concern will be identified. Based on the findings of the assessment, a range of actions points may be generated. All referrals will be made through the usual channels. Issues that have arisen from the assessment will be clearly recorded on the HELP-COPD action plan and by ensuring that all agencies and the patient have copies of the plan it is hoped that the planned action points will be reviewed and implementation facilitated. The action plan will be reviewed by the study nurse who will contact the patient at 1, 3 and 6 months to check progress with action points.
Study NCT04562350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XatJove Anoia Aplication
Description: All students (age 12-16 years) from middle school and high school in the sanitary region of Anoia, province of Barcelona, will access a Platform ( ABH Health), where the users will enter specific registration data ( age, sex..etc), after every visit the users will be provided with a 6 multiple choice questionary and asked to punctuate in a scale from 1 to 10, the satisfaction of the service provided. Appart from this data, researchers will use a software to register specific Health-related words and classify them as Health-problems. While Osona students will attend face-to-face consultations as usual, apart from this data,Registrations will be reviewed later and specific search techniques and strategies will be coded. A qualitative review will be performed too.
Study NCT00444535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1500 mg oral lapatinib (once daily)